IMMUNO-ONCOLOGY XCHANGE
2024
San Diego, February 27th

Welcome to hubXchange’s Immuno-Oncology Xchange San Diego 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions.
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, and Cell Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Handlery Hotel San Diego, 950 Hotel Circle North, San Diego CA 92108

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Immune Biomarkers

Predictive biomarkers for IO treatment used in clinical practice now and in the future
The rise of spatial omics technologies and their potential for new biomarker discovery

Track 2: Translational Research

Translational strategies to develop clinically safe and effective immune cell engagers
How to select the right translational screening model to monitor IO agents

Track 3: Clinical Development

Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
How to maximize clinical success: Patient selection strategies beyond target expression

Track 4: Cell Therapies

Exploring different cellular modalities
TME-targeting combinations – improving efficacy

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Overcoming Limited Tumor Tissue Availability: Biomarker Identification in Blood for Improved Cancer Diagnosis and Monitoring

Advantages and Limitations of Each Approach: What are the pros and cons of each approach?
Comprehensive Blood-Based Assessment: Can blood measurements comprehensively address all biomarker and monitoring questions?
Validation of Blood-Based Approaches: Is it necessary to evaluate both approaches for validation when considering a blood-based approach exclusively?
Mandatory Tumor Tissue Biopsies in Clinical Trials: Can tumor tissue biopsies be a mandatory requirement in clinical trials for any indications?

Sonia Feau, Director of Biology, Onchilles Pharma

Sonia Feau is Director of Biology at Onchilles Pharma and is responsible for managing activities related to the overall execution of R&D initiatives to move innovative therapeutic drug candidates into the clinic and advance Onchilles’ platform and future product portfolios.
Sonia has 20 years of immuno-oncology experience. Prior to Onchilles Pharma, Sonia worked at Oncorus where she led the Immunology group responsible for designing, optimizing and evaluating new immune enhancer payloads to be expressed by oncolytic viruses, at Merck & Co. and Merrimack Pharmaceuticals, she proposed and evaluated several new immuno-oncology targets.
Sonia’s experience in Immunology spans both innate and adaptive immune responses. She received her post-doctoral training at the La Jolla Institute for Immunology in San Diego, where she studied CD8 memory T cells. Sonia received her Ph.D. in Immunology and Biotechnology from the University of Milano-Bicocca, Italy and University Toulouse III, France studying dendritic cells biology.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

14:55 – 15:05

Afternoon Refreshments

15:05 – 15:35

Poster Session by Bio-Rad

Anti-TIGIT antibody discovery

Birthe Jessen-Park, Technical Sales Specialist, Custom Antibody Service, Bio-Rad

15:40 – 16:40

Pharmacodynamic and predictive biomarkers: Choosing the right strategy from preclinical to clinical stages

16:40 – 17:40

Drinks-Canape Reception

Translational Research

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Developing immune cells with better in vivo persistence

How to maintain immune cell capacity in vitro
How to improve the persistence and function of immune cells in vivo
How to improve the efficacy of allogenic immune cell therapy

Xiaomei Yuan, Director, CAR T cell therapy, Sorrento Therapeutics

She is a passionate immunologist and adept team leader deeply devoted to advancing cancer immunotherapy. Her focus lies in pioneering allogenic CAR T and iPSC-CAR NK therapies to combat cancer. With a strong foundation in research and leadership, she is committed to driving innovation, fostering collaboration, and shaping the future of cancer treatment through cutting-edge immuno-oncology solutions.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

14:55 – 15:05

Afternoon Refreshments

15:05 – 15:35

Poster Session

15:40 – 16:40

Translational strategies to develop clinically safe and effective immune cell engagers

Shyam Sarikonda, Director, Legend Biotech

Scientific Leader in Immuno-Oncology and Cell & Gene Therapy Drug Development. Trained immunologist with expertise in translational research and preclinical and clinical biomarker development for CAR-T, Immuno-oncology and small molecule therapies for Phase I/II or III clinical trials. Advanced R&D goals through collaboration with KOLs leading to multiple peer reviewed manuscripts. Led the publication of cross-industry white paper in CAR-T immune monitoring. Mentored multiple associates in efficiently managing projects to achieve time- and business-critical goals. Evaluated and implemented new technologies for scientific advancements (e.g., HPFC) and laboratory automation solutions (Liquid handlers) as well as data analysis (AI based flow cytometry data analysis). Championed the development, validation and implementation (under GXP regulations) of multiple biomarker monitoring panels (>30) in AML/CLL/MM/AML and DLBCL etc., disease settings. Proficient at business development project proposals and portfolio prioritization. Experienced in regulatory document submissions including BAR/BDR and briefing books

16:40 – 17:40

Drinks-Canape Reception

Clinical Development

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Intratumoral Immunotherapy: new approaches in clinical development to improve treatment efficacy

Analysis of the tumor microenvironment (TME) in different cancer indications and its role in selecting optimal therapeutic approaches
How reprogramming various facets of the TME (e.g. blood vessels, myeloid cells, and
regulatory T cells) may overcome TME-instigated resistance mechanisms to immunotherapy
How to incorporate various immunotherapies into clinical practice to improve immunotherapy outcomes

Boris Minev, President, Medical and Scientific Affairs, Calidi Biotherapeutics, Inc.

Dr. Boris Minev is a physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development.

Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing translational projects on oncolytic virotherapy, immunotherapy and nanotechnology.

Dr. Minev is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

14:55 – 15:05

Afternoon Refreshments

15:05 – 15:35

Poster Session

15:40 – 16:40

Improving clinical trial methods in cell and gene therapy

Matthew Spear, Chief Development Officer/ Chief Medical Officer, Denovo Biopharma

16:40 – 17:40

Drinks-Canape Reception

Cell Therapies

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Keynote Presentation

9:05 – 10:05

Overcoming TME challenges in treating solid tumours using T cell therapies

High tumor burden versus CART dysfunction
Immune desert tumors versus CART infiltration
Target downregulation, off tumor expression versus CAR sensitivity

Yannick Bulliard, Senior Director, Research, Appia Bio

Yannick Bulliard is currently Sr Director of Research at Appia Bio, working on the development off-the-shelf, hematopoietic stem cell-derived CAR+ gd and NKT cells for the treatment of cancer. Yannick has over a decade of immunotherapy development experience, at various companies small and large.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

14:55 – 15:05

Afternoon Refreshments

15:05 – 15:35

Poster Session

15:40 – 16:40

Controlling cell trafficking of CAR-T cells to solid tumour sites

Antonio Santridian, CSO, Calidi Biotherapeutics, Inc.

16:40 – 17:40

Drinks-Canape Reception

IMMUNO-ONCOLOGY XCHANGE2024San Diego, February 27th

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Immune Biomarkers

Partners

IMMUNO-ONCOLOGY XCHANGE
2024
San Diego, February 27th